Thanks to Dr Yamshon and @johnpleonardmd.bsky.social for your excellent editorial: Unstacking the deck in follicular lymphoma clinical trials url: academic.oup.com/jnci/article... In response to our paper here: academic.oup.com/jnci/article...

T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma - Wight - 2025 - eJHaem - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...

Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival url: academic.oup.com/jnci/article...

Please join us on 1 August for the inaugural open meeting of the OPTIMAL CRE in improving immunoglobulin use! www.optimalcre.org We'll have updates on research projects underway, and lots of opportunities to join the discussion. Registration details below. Everyone is welcome, in person or online!

Our multidisciplinary study of RT + immunotherapy with CD8 PET as a biomarker of response in relapse B-NHL ashpublications.org/bloodadvance...

Thanks to all who stopped by to chat with us at our #FollicularLymphoma #EHA2025 poster 👋 @hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

We're also showcasing our #18ICML posters: -221, real-world data on end-of-treatment imaging #TCellLymphoma; -390, Ki67 expression level in #FollicularLymphoma See you June 18👋 @icmlugano.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL. • operationally deliverable with ctDNA turnaround median 9d • low rate PET+ and ctDNA+ at interim • assessing whether acala addition benefits those with Myd88 &/or CD79b mutns SAKK38/19 trial #ICML18

PROs from BRUIN-321 pirto vs idelaR/BR R/R CLL #18ICML - pirto: better improvements in CLL-related sx, physical function, fatigue, all clinically significant - 83% PRO completion pirto at week 25, only 59% other arm Grain of salt given PRO dropout, but well reported. #lymsm

We're excited to meet you at our #EHA2025 poster PS1885 to talk about the study of Ki67 expression in Australasian #FollicularLymphoma patients. See you Saturday, June 14 👋 @hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social #LymphomaResearch #ClinicalResearch #Registry

Join us now at our poster in #ASCO2025 to discuss gender demographics and equity in professional opportunities!

Pleased to work with my U.K. colleagues this analysis of PET data from our CHEMO-T study in PTCL led by #drgleeson and #drchua onlinelibrary.wiley.com/doi/10.1111/...

The Lymphoma and Related Diseases Registry enrolled the ⭐9000th⭐ participant on May 8, 2025! We would like to express our sincere gratitude to all participants, participating sites and staff, principal investigators and industry partners for their continued support of the registry 🙌

Our study showing 3D volume assessment of PCNSL on MRI is more accurate than standard criteria in response assessment and prognostication. academic.oup.com/noa/advance-...

Join us tomorrow for last webinar of this series "Careers in Pharma" with Dr Connie Batlevi & Jamie Hirata along with Casulo Carla & Judith Trotman Register at us06web.zoom.us/webinar/regi...

📢 We are excited to announce that the #18ICML Scientific Programme IS ONLINE: shorturl.at/FlsmC Thank you to our international Advisory Board and reviewers for their precious help!

Don't miss the last webinar of this series next week with Connie Batlevi & Jamie Hirata presenting on Careers in Pharma along with Casulo Carla & @judithtrotman.bsky.social ! Register at us06web.zoom.us/webinar/regi...

Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma buff.ly/2sCOERm #hemesky #bloodspotlight #lymphoidneoplasia

LaRDR supports early-career clinician-researchers by providing #research opportunities📊. They gain experience in manuscript writing ✍️ for publication and conference presentations. Tune in to this interview to hear more from Dr Wang! 🎬 youtu.be/0rjytiYHhuY

Join Dr Julia Brain & Dr Candice McCoy tomorrow @ 4pm EST for the 3rd webinar of this series "Successful Research Collaboration", hosted by our Steering Committee members Dr Carla Casulo , Dr Wendy Osborne & Dr Ann LaCasce Register @ us06web.zoom.us/webinar/regi...

Spreading the word about MyHodgkin MyHealth: Our interview with @normanswan on ABC Radio’s Health Report. MHMH is open now in Australia for any HL survivors to join abc.net.au/listen/program… @janfalconer

Join us tomorrow for session 2 where John Wahba, Suhaida Selamat and Clare Spooner will present on Industry Engagement. To register: us06web.zoom.us/webinar/regi... With thanks to @astrazeneca.bsky.social & Lymphoma Australia

I was very active in helping the MRFF come about. It was always intended to disburse around $1b a year if fully capitalized at $20b. The fund has well exceeded that, now at $22b+, yet it only disburses $650m/year, 1/

Our WiLing Wednesday Webinar Series 14 "Demystifying Pharma" starts tomorrow with Session 1 on Pharma Structure. To register: us06web.zoom.us/webinar/regi... Upcoming sessions: April 23 - Industry Engagement April 30 - Successful Research Collaborations May 7 - Careers in Pharma

@lardr.bsky.social Welcome to @bsky.app !

Congratulations to our Chair Anna Sureda, as well as Steering Committee members Astrid Pavlovsky, Michelle Poon and Sonali Smith, for the recent publication of your article in the Lancet Haematology!!

Well done to #drarinamartynchyk and #a/profmaryannanderson for leading this Australasian Lymphoma registry study on CLL and risk of second skin malignancy. Still an issue with patients getting novel agents. onlinelibrary.wiley.com/doi/full/10.... lardr.org.au

Welcome to @bsky.app ejHaem! Follow them here ➡️ @ejhaem.bsky.social

📢 ONJCRI is thrilled to welcome Dr Teresa Sadras, Head of the Leukaemia Biology & Functional Genomics Lab! Her research explores treatment resistance in B-ALL, leukaemia vulnerabilities & precise tumour models. Join us in welcoming Dr Sadras to the team! 🎉

Very proud of my team #drcamlewis and @allibarraclough.bsky.social for co-authoring this review out in @bloodjournal.bsky.social today. ashpublications.org/blood/articl...

THE LEUKEMIA & LYMPHOMA SOCIETY DENOUNCES FEDERAL ACTIONS THAT THREATEN CANCER PATIENTS www.lls.org/news/leukemi...

SYMPATICO trial - RCT of venetoclax + ibrutinib vs ibr+placebo in R/R mantle cell lymphoma just out in Lancet Oncology www.sciencedirect.com/science/arti... #lymphoma #lymsm

Fixed-duration acala combos 1L CLL AMPLIFY trial @nejm.org #lymsm - 867 pts, ~60% uIGHV, no TP53/del17 - 3-yr PFS AVO 83%, AV 77% >> BR/FCR 67% - uIGHV: 3-yr PFS AVO 83%, AV 69%, BR/FCR 57% - OS better w/ AV vs BR/FCR (not AVO) - AV w/ fewest TRAEs New oral SOC? www.nejm.org/doi/full/10....

Censor CDC scientists and ask them to withdraw papers from medical journals? This is not how it works, Mr President. Our response @bmj.com on the Trump Executive Order and his "forbidden words" www.bmj.com/content/388/...

If you haven’t already today would be day to leave the other platform www.bbc.com/news/article...

Another lymphoma @bloodadvances.bsky.social paper from our group. A review done by Dr Luke Wang: phase 3 lymphoma randomised trials, definitions of 2D bulk and its use in the design varies significantly across and within lymphoma subtypes. ashpublications.org/bloodadvance...

Excited that our investigator let study in treatment naive follicular lymphoma is published!

FDA approves acala+BR for 1L MCL based on the ECHO trial. Thoughts from #lymsm based on the lack of OS benefit and tox issues? Concurrent vs sequential.

Our #lymsm patients are exposed to significant doses of steroids & chemo that reduces bone density. Congrats to my colleague Dr Douglas for leading our study in #Haematologica that shows we can identify those at risk on the CT component of their staging PET/CT & intervene doi.org/10.3324/haem...

“The impact of the collective executive orders and directives appears devastating.” scim.ag/40ureTO

So proud of my new PhD student Zoe Loh for her NHMRC scholarship. Exciting times ahead for her project in mantle cell lymphoma.

Five of the six plenary abstract presenters are women, several of them quite junior. #ASHKudos to the mentors/sponsors/blinded abstract review that brought us this monumental speaker lineup! #ASH24

So pleased to add our small contribution to the outstanding #ASH2024 education program booklet this year with Dr Allison Barraclough. ashpublications.org/hematology/a...

Well done to my fellow Marsali MacLean. Our #ash24 abstract reporting toxicity reporting in phase 1 trials made it to #2 on #leonardslist thank you @johnpleonardmd.bsky.social !! Check it out here: ash.confex.com/ash/2024/web...

Fantastic meeting this afternoon of the global Lymphoma Registry Alliance, in partnership with Lymphoma Coalition representing patients around the world: lymphomacoalition.org). Thanks @elizahawkes.bsky.social for your leadership in bringing us together, and to all for participating.

Join us for our Post-ASH 2024 #CLL Highlights Webinar!🔬🩸 Presentations & discussions on selected abstracts from #ASH24 🗓️ 23 Jan 2025 Chair: Barbara Eichhorst | Moderators: Matthew Davids & Kerry Rogers 👉https://buff.ly/4hSDgxY #CLLsm #LeuSM

We're so excited for our Post-ASH 2024 Highlights Webinar Series!🩸 Presentations & discussions on selected abstracts from #ASH24 Featuring leading #HemOnc experts 👉https://ow.ly/zc9Z50U6Nkp #LeuSM #MPNsm #MMsm #LymSM #MDSsm

Our multidisciplinary team identified that in #lymsm patients having anthracycline, coronary artery calcium measured on baseline PET/CT predicts cardiac events ashpublications.org/bloodadvance... #hemesky @onjcri.bsky.social

@ash-hematology.bsky.social Welcome to Bluesky great to have you here.